Literature DB >> 20730472

Temporal lobe pleomorphic xanthoastrocytoma and acquired BRAF mutation in an adolescent with the constitutional 22q11.2 deletion syndrome.

Jeffrey C Murray1, David J Donahue, Saleem I Malik, Yvette B Dzurik, Emily Z Braly, Margaret J Dougherty, Katherine W Eaton, Jaclyn A Biegel.   

Abstract

DiGeorge syndrome, or velocardiofacial syndrome (DGS/VCFS), is a rare and usually sporadic congenital genetic disorder resulting from a constitutional microdeletion at chromosome 22q11.2. While rare cases of malignancy have been described, likely due to underlying immunodeficiency, central nervous system tumors have not yet been reported. We describe an adolescent boy with DGS/VCFS who developed a temporal lobe pleomorphic xanthoastrocytoma. High-resolution single nucleotide polymorphism array studies of the tumor confirmed a constitutional 22q11.21 deletion, and revealed acquired gains, losses and copy number neutral loss of heterozygosity of several chromosomal regions, including a homozygous deletion of the CDKN2A/B locus. The tumor also demonstrated a common V600E mutation in the BRAF oncogene. This is the first reported case of a patient with DiGeorge syndrome developing a CNS tumor of any histology and expands our knowledge about low-grade CNS tumor molecular genetics.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20730472      PMCID: PMC2998545          DOI: 10.1007/s11060-010-0350-2

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  19 in total

1.  Histopathological features of recurrent pleomorphic xanthoastrocytomas: further corroboration of the glial nature of this neoplasm. A study of 3 cases.

Authors:  J J Kepes; L J Rubinstein; L Ansbacher; D J Schreiber
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

2.  Pleomorphic xanthoastrocytoma: favorable outcome after complete surgical resection.

Authors:  M Fouladi; J Jenkins; P Burger; J Langston; T Merchant; R Heideman; S Thompson; A Sanford; L Kun; A Gajjar
Journal:  Neuro Oncol       Date:  2001-07       Impact factor: 12.300

Review 3.  The 22q11.2 deletion syndrome.

Authors:  B S Emanuel; D McDonald-McGinn; S C Saitta; E H Zackai
Journal:  Adv Pediatr       Date:  2001

4.  Frequent loss of chromosome 9, homozygous CDKN2A/p14(ARF)/CDKN2B deletion and low TSC1 mRNA expression in pleomorphic xanthoastrocytomas.

Authors:  R G Weber; A Hoischen; M Ehrler; P Zipper; K Kaulich; B Blaschke; A J Becker; S Weber-Mangal; A Jauch; B Radlwimmer; J Schramm; O D Wiestler; P Lichter; G Reifenberger
Journal:  Oncogene       Date:  2006-08-07       Impact factor: 9.867

5.  Chromosome 22-specific low copy repeats and the 22q11.2 deletion syndrome: genomic organization and deletion endpoint analysis.

Authors:  T H Shaikh; H Kurahashi; S C Saitta; A M O'Hare; P Hu; B A Roe; D A Driscoll; D M McDonald-McGinn; E H Zackai; M L Budarf; B S Emanuel
Journal:  Hum Mol Genet       Date:  2000-03-01       Impact factor: 6.150

Review 6.  Malignancy in chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome).

Authors:  Donna M McDonald-McGinn; Anne Reilly; Carina Wallgren-Pettersson; H Eugene Hoyme; Samuel P Yang; Margaret P Adam; Elaine H Zackai; Kathleen E Sullivan
Journal:  Am J Med Genet A       Date:  2006-04-15       Impact factor: 2.802

7.  Detailed analysis of 22q11.2 with a high density MLPA probe set.

Authors:  G R Jalali; J A S Vorstman; Ab Errami; R Vijzelaar; J Biegel; T Shaikh; B S Emanuel
Journal:  Hum Mutat       Date:  2008-03       Impact factor: 4.878

Review 8.  BRAF(E600) in benign and malignant human tumours.

Authors:  C Michaloglou; L C W Vredeveld; W J Mooi; D S Peeper
Journal:  Oncogene       Date:  2007-08-27       Impact factor: 9.867

9.  High-density single nucleotide polymorphism array analysis in patients with germline deletions of 22q11.2 and malignant rhabdoid tumor.

Authors:  Eric M Jackson; Tamim H Shaikh; Sridharan Gururangan; Marilyn C Jones; David Malkin; Sarah M Nikkel; Craig W Zuppan; Luanne M Wainwright; Fan Zhang; Jaclyn A Biegel
Journal:  Hum Genet       Date:  2007-05-31       Impact factor: 4.132

10.  Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas.

Authors:  David T W Jones; Sylvia Kocialkowski; Lu Liu; Danita M Pearson; L Magnus Bäcklund; Koichi Ichimura; V Peter Collins
Journal:  Cancer Res       Date:  2008-11-01       Impact factor: 12.701

View more
  5 in total

Review 1.  Aggressive behavior and anaplasia in pleomorphic xanthoastrocytoma: a plea for a revision of the current WHO classification.

Authors:  Nesibe Kahramancetin; Tarik Tihan
Journal:  CNS Oncol       Date:  2013-11

2.  BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications.

Authors:  Dora Dias-Santagata; Quynh Lam; Kathy Vernovsky; Natalie Vena; Jochen K Lennerz; Darrell R Borger; Tracy T Batchelor; Keith L Ligon; A John Iafrate; Azra H Ligon; David N Louis; Sandro Santagata
Journal:  PLoS One       Date:  2011-03-29       Impact factor: 3.240

3.  Constitutional chromosomal events at 22q11 and 15q26 in a child with a pilocytic astrocytoma of the spinal cord.

Authors:  Samantha Mascelli; Mariasavina Severino; Alessandro Raso; Paolo Nozza; Elisa Tassano; Giovanni Morana; Patrizia De Marco; Elisa Merello; Claudia Milanaccio; Marco Pavanello; Andrea Rossi; Armando Cama; Maria Luisa Garrè; Valeria Capra
Journal:  Mol Cytogenet       Date:  2014-05-15       Impact factor: 2.009

4.  Risk of malignancy in 22q11.2 deletion syndrome.

Authors:  Toer Stevens; Jutte van der Werff Ten Bosch; Marjan De Rademaeker; Ann Van Den Bogaert; Machiel van den Akker
Journal:  Clin Case Rep       Date:  2017-03-02

5.  Significant evidence of linkage for a gene predisposing to colorectal cancer and multiple primary cancers on 22q11.

Authors:  Craig Teerlink; Quentin Nelson; Randall Burt; Lisa Cannon-Albright
Journal:  Clin Transl Gastroenterol       Date:  2014-02-27       Impact factor: 4.488

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.